Paper - WANFANG MED ONLINE

You Position: Home > Paper

Splenic tyrosine kinase promotes pulmonary angiogenesis in rats with hepatopul-monary syndrome

( views:30, downloads:0 )

Author:: No author available

Journal Title:: Acta Physiologica Sinica

Issue:: 6

DOI:: 10.13294/j.aps.2020.0087

Key Word:: 脾脏酪氨酸激酶;肝肺综合征;血管新生;Erk1/2;Akt

Abstract：本研究旨在研究脾脏酪氨酸激酶(spleen tyrosine kinase,Syk)在肝肺综合征(hepatopulmonary syndrome,HPS)血管新生过程中的作用及其机制.Sprague Dawley(SD)大鼠随机分为3组:假手术组(Sham组)、胆总管结扎(common bile duct ligation,CBDL)5周组(5W组)和R788药物干预组(R788组),通过CBDL术进行HPS造模,R788组大鼠在CBDL术后每日腹腔注射1次R788(20 mg/kg)至第5周.用Western blot和免疫组织化学法检测Syk、p-Erk1/2、p-Akt在肺组织中的表达和分布情况,用免疫荧光染色法观察Syk在肺中的定位和肺组织血管新生数目.结果显示,相对Sham组,5W组大鼠Syk蛋白表达水平显著上调,Erk1/2和Akt磷酸化水平显著上调,肺微血管数量显著增加;相对5W组,R788组大鼠Syk蛋白表达水平显著下调,Erk1/2和Akt磷酸化水平显著下调,肺微血管数量显著减少.以上结果表明,Syk可能通过激活下游Erk1/2和Akt信号转导通路促进HPS模型大鼠肺内血管新生,这为HPS的临床治疗提供了理论依据和潜在药物治疗靶点.

Reference

[1].Progress in investigating the pathogenesis of hepatopulmonary syndrome[J].2010,(4).
[2]Lionello,M.,Staffieri,A.,Marioni,G..Potential prognostic and therapeutic role for angiogenesis markers in laryngeal carcinoma[J].2012,132(6).
[3]Buharalioglu, Cuneyt K.,Chi Young Song,Yaghini, Fariborz A.,etc.Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation.[J].2011,70(3).
[4]Sarah, Raevens,Anja, Geerts,Annelies, Paridaens,etc.Placental growth factor inhibition targets pulmonary angiogenesis and represents a novel therapy for hepatopulmonary syndrome in mice.[J].2017,(Spec ).
[5]Miyake,M.,Goodison,S.,GomesGiacoia,E.,etc.Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways[J].2013,93(7).
[6]Gao, Jing,Chen, Lin,Zeng, Jing,etc.The involvement of aquaporin 1 in the hepatopulmonary syndrome rat serum-induced migration of pulmonary arterial smooth muscle cells via the p38-MAPK pathway[J].2015,11(11).
[7]Delong, Liu,Aleksandra, Mamorska-Dyga.Syk inhibitors in clinical development for hematological malignancies.[J].2017,10(1).
[8]Deng, Zihou,Ma, Shixin,Zhou, Hao,etc.Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal T(H)17 responses[J].2015,16(6).
[9]Fruchon,S.,Bezombes,C.,AlSaati,T.,etc.Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis[J].2012,26(4).
[10]Valentin Fuhrmann,Christian Madl,Christian Mueller,etc.Hepatopulmonary Syndrome in Patients With Hypoxic Hepatitis[J].2006,131(1).
[11]Yang, Y.,Chen, B.,Chen, Y.,etc.A comparison of two common bile duct ligation methods to establish hepatopulmonary syndrome animal models[J].2015,49(1).
[12]Ichiro, Shiojima,Kenneth, Walsh.Role of Akt signaling in vascular homeostasis and angiogenesis.[J].2002,90(12).
[13]Rosen,C.B.,Swanson,K.L.,Heimbach,J.K.,etc.Hepatopulmonary syndrome: Favorable outcomes in the MELD exception era[J].2013,57(6).
[14]P Schenk,V Fuhrmann,C Madl,etc.Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences[J].2002,51(6).
[15]Savale L,Herve P,Le-Pavec J,etc.Pulmonary vascular abnormalities in cirrhosis.[J].2007,21(1).
[16]CHEN FU,BAOXIN CHEN,XIANGLAN JIN,etc.Puerarin protects endothelial progenitor cells from damage of angiotensin II via activation of ERK1/2?Nrf2 signaling pathway.[J].2018,17(3).
[17]Schaefer Cutillo J,De Vos S,Leonard JP,etc.Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.[J].2010,115(13).
[18]Danial, Matluobi,Atefeh, Araghi,Behnaz Faramarzian Azimi, Maragheh,etc.Carvacrol promotes angiogenic paracrine potential and endothelial differentiation of human mesenchymal stem cells at low concentrations.[J].2017,(Spec ).
[19]Alhazmi, Alaa.Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection[J].2018,10(4).
[20]Stergios Soulaidopoulos,Evangelos Cholongitas,George Giannakoulas,etc.Review article: Update on current and emergent data on hepatopulmonary syndrome[J].2018,(12).
[21]Razorenova OV,Byzova TV,Somanath PR,etc.Akt1 in endothelial cell and angiogenesis.[J].2006,5(5).
[22]Karen L. Swanson,Russell H. Wiesner,Michael J. Krowka.Natural history of hepatopulmonary syndrome: Impact of liver transplantation[J].2005,41(5).
[23]Geahlen,R.L..Getting Syk: Spleen tyrosine kinase as a therapeutic target[J].2014,35(8).
[24].miRl44-3p inhibits PMVECs excessive proliferation in angiogenesis of hepatopulmonary syndrome via Tie2[J].2018,365(1).
[25]Stockard CR,Tang L,Zhang J,etc.Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome.[J].2003,38(5).
[26]Mocsai A,Ruland J,Tybulewicz VL.The SYK tyrosine kinase: a crucial player in diverse biological functions.[J].2010,10(6).
[27]C, Liebmann.Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity.[J].2001,13(11).
[28]Hoerning,A.,Raub,S.,Neudorf,U.,etc.Pulse oximetry is insufficient for timely diagnosis of hepatopulmonary syndrome in children with liver cirrhosis[J].2014,164(3).
[29]Stachon P,Hoppe N,Hilgendorf I,etc.The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.[J].2011,31(9).
[30].Hepatopulmonary syndrome: Update on pathogenesis and clinical features[J].2012,9(9).
[31]Liu, Chang,Gao, Jing,Chen, Bing,etc.Cyclooxygenase-2 promotes pulmonary intravascular macrophage accumulation by exacerbating BMP signaling in rat experimental hepatopulmonary syndrome[J].2017,138.
[32]Geahlen RL.Syk and pTyr'd: Signaling through the B cell antigen receptor.[J].2009,1793(7).
[33]Zhao F,Schoettler N,Wang S,etc.Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.[J].2007,124(3).